News

Cortivera-H has been approved for pharma care reimbursement program in the BC formulary, and is in the process to get listed in other provincial formularies. Cortivera-H, a made

Deerfield Management Company led the series B financing round, which included participation from OrbiMed Advisors, Clarus Ventures, and Hatteras Venture Partners. Graybug will use the proceeds to further

In a study on mice, researchers found that the drugs, called Hsp90 inhibitors, were found to strip cancer cells of defences against hormone treatments. The research indicates that

Fycompa is already available in 43 countries in 2 mg, 4 mg, 6 mg, and 8 mg, 10 mg, and 12 mg tablets. The updated formulation is now

Based in our Hatton Garden office, London, UK , the successful candidate will be required to work on multiple projects, working with in-house sales, production, marketing, and editorial

The payment was triggered by the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Novartis Phase I study

CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco®. The clinical trial results continue to support the development of CTP-656 as

BiCNU is primarily used for chemotherapy in the treatment of several types of brain cancer, multiple myeloma and lymphoma (Hodgkin’s and non-Hodgkin). BiCNU is also sometimes used for

TAF is a novel targeted prodrug of tenofovir that has showed high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir